What is HeartBeam's gross profit margin?

What is the revenue and EPS growth rate for HeartBeam year over year?

Did HeartBeam beat or miss consensus estimates last quarter?

What guidance did HeartBeam's management provide for the next earnings period?

What factors drove the changes in HeartBeam's revenue and profit?

What is HeartBeam's latest dividend and current dividend yield?

What does HeartBeam do and what are its main business segments?

What is the market's earnings forecast for HeartBeam next quarter?

- **FDA Clearance Imminent**: 12-Lead ECG synthesis software clearance expected by year-end, enabling commercial launch in early 2026.
- **Partnership Strength**: HeartNexus provides nationwide cardiologist coverage, enhancing patient access to timely ECG interpretations.
- **Financial Resilience**: Q3 2025 cash position of $1.9 million reflects disciplined spending, with plans to strategically fund growth without excessive dilution.
- **Market Expansion**: Initial focus on Southern California and South Florida, with potential for broader expansion post-positive user feedback.
- **Innovation Pipeline**: Exploring additional indications like myocardial infarction detection, positioning HeartBeam for long-term growth.

**【CEO Summary Section】**
- **FDA Milestones**: Anticipated FDA clearance for 12-Lead ECG synthesis software by end of 2025, enabling commercial launch. The VALID-ECG study demonstrated 93.4% diagnostic agreement with standard 12-Lead ECGs.
- **Partnership Highlights**: Signed agreement with HeartNexus for on-demand cardiologist reviews, enhancing patient access to clinical-grade ECGs.
- **Commercial Strategy**: Initial launch focused on Southern California and South Florida, targeting concierge and preventive cardiology practices. Subscription model includes upfront fees and limited cardiology reads, with potential expansion to automated assessments post-FDA clearance.

**【CFO Financial Commentary】**
- **Financial Health**: Ended Q3 2025 with $1.9 million in cash, maintaining financial discipline with an 8% quarter-over-quarter decrease in operating expenses.
- **Funding Approach**: Balancing strategic investments with shareholder dilution, exploring options for capital markets expansion post-FDA clearance.

**【Q&A Key Highlights】**
- **FDA Discussions**: Productive interactions with FDA, no major issues identified; clearance timeline remains on track.
- **Manufacturing Readiness**: U.S.-based contract manufacturer with off-the-shelf components ensures scalability; workflow optimization is a key focus.
- **Future Indications**: Exploring regulatory pathways for myocardial infarction detection, with initial discussions with FDA underway.
- **Funding Strategy**: Optionality in funding sources, prioritizing strategic partnerships to minimize dilution.

BEAT

BEAT fundamentals

You can ask Aime